Doctor Jerry A. Shields is Director Emeritus of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia.
After graduating from the University of Michigan Medical School, he completed a residency in ophthalmology at Wills Eye Hospital and completed post-residency fellowships in ophthalmic pathology and retinal surgery. For 40 years, Dr. Shields has been active in the care of patients with ocular tumors and in clinical research to improve methods for the diagnosis and treatment of eye cancers. He and his associates have a full time practice devoted to tumors and pseudotumors of the eyelids, conjunctiva, intraocular structures, and orbits.
Dr. Shields’ main contributions have been in the treatment of malignant melanoma, which affects the eyes of adults, and retinoblastoma, which affects the eyes of children. With regard to melanoma, Dr. Shields and his associates have improved and popularized techniques of local irradiation, local surgical resection, laser photocoagulation, and thermotherapy. He has contributed enormously to our understanding of ocular tumors.
With regard to retinoblastoma, Dr. Shields and associates have been active in improving detection of retinoblastoma and treatment techniques of chemoreduction, intra-arterial chemotherapy, intravitreal chemotherapy, local irradiation, laser photocoagulation, and thermotherapy. The development and refinement of these techniques have contributed greatly to saving many eyes that would have been removed in the past. He has also made research contributions in the diagnosis and treatment of many other benign and malignant tumors, such as tumors of the ciliary body epithelium, pigment epithelium, and leiomyomas.
Dr. Jerry Shields has published more than 1500 medical articles and textbook chapters and has authored or co-authored 11 major textbooks related to ocular tumors. Click on the following textbook covers to view his publications on Amazon.
Dr. Shields has lectured widely, including over 35 named lectures, and has received national and international recognition for his contributions in the field of ocular oncology. He was chosen as the first President of the International Society of Ocular Oncology, an honor to which he lead all physicians in the field of ocular oncology during his 2 year term.